SEMASEARCH Study Design: Real-World Evaluation of Semaglutide [amount hidden] in Adults With Severe Obesity Underrepresented in Clinical Trials

What Was Tested

This observational study looks at Semaglutide.

The study also intends to characterize weight loss response in pre-defined subgroups of patients and to identify predictors of weight loss using machine learning.

Why It Was Studied

It will also address major knowledge gaps in specific populations underrepresented in clinical trials and generate predictive models of weight loss response.

Who Took Part

The abstract describes 4 individuals taking part.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

A total of 1100 patients with severe obesity (BMI ≥ 40 kg/m2 with at least one treated obesity-related complication) were retrospectively included from 11 expert obesity centers, based on prospectively collected data at baseline, 6 months, and 12 months.

Subgroups include patients with a history of bariatric surgery, binge eating disorder, hypothalamic obesity, age ≥ 60 years or altered body composition, BMI ≥ 60 kg/m2, and those receiving psychotropic medications.

How the Study Was Run

The design is described as multicenter.

Running at several centres spread the Semaglutide study over different clinics and patient groups.

Assessments include clinical, biological, and body composition data, as well as standardized questionnaires evaluating eating behaviour, physical activity, sleep, quality of life, digestive symptoms, and mental health.

What Was Measured

PubMed files the paper under topics including Semaglutide, Obesity, Morbid, Glucagon-Like Peptides, Weight Loss, Anti-Obesity Agents, France and Patient Reported Outcome Measures.

The authors tagged it with the keywords GLP‐1 analogue, antiobesity drug, cohort study, obesity care and real‐world evidence.

What This Means in Plain Language

The paper is a multicenter study of Semaglutide in 4 individuals.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 2 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Semaglutide compound page, all human trials.